<DOC>
	<DOC>NCT00964678</DOC>
	<brief_summary>The purpose of this study is to determine whether carvedilol treatment of patients with pulmonary arterial hypertension and associated right heart failure is safe and results in an improved function of the right heart.</brief_summary>
	<brief_title>Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>idiopathic, familial or associated PAH, WHO group 1 NYHA class II or III clinically stable with optimized PAH treatment for at least 3 months no or minimal evidence of fluid overload or volume depletion, with or without diuretic treatment age &gt; 18 years mean pulmonary artery pressure (mPAP) &gt; 25 mmHg 6 minute walk distance (6MWD) over 100m Structural heart disease unrelated to PAH Recent (&lt;3 months) treatment with an intravenous positive inotropic agent current use of βblockers history of reactive airways disease history of adverse reaction to βblockers heart block on ECG or resting heart rate &lt; 60 bpm cardiac index &lt; 1.8 l/min/m2 systemic hypotension (systolic pressure &lt; 90 mmHg) pulmonary capillary wedge pressure &gt; 15 mmHg inability to give informed consent contraindications to CT and/or PET scanning coagulopathy (INR&gt;1.5 or platelet count&lt;50000/mm3) severe renal insufficiency (creatinine clearance &lt;30 ml/min/m2) malignancy or any comorbidity limiting survival or conditions predicting inability to complete the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>